tc 2

TC-F 2 is a FAAH inhibitor.

AAL Toxin TC2 is a useful organic compound for research related to life sciences and the catalog number is T125566.

TC-N 22A is a strong, selective, oral active mGlu4 forward allosteric regulator (PAM) that can cross the blood-brain barrier. EC50 expression of TC-N 22A in BHK cells expressing human mGlu4 was 9 nM. TC-N 22A showed very low activity against mGlu 1, 2, 3, 5, and 7 receptors in excitation and forward allosteric models (EC50 >10 μM). TC-N 22A can be used in the study of central nervous system diseases.

GPR35 agonist 2 (TC-G 1001) is a potent GPR35 agonist.The EC50 values of GPR35 agonist 2 in the β-arrestin and Ca2+ release assays were 26 and 3.2 nM, respectively.

PBD dimer-2 (compound 2c), a C8-linked pyrrolobenzodiazepine dimer, has the capability to span an extra base pair and cross-link the 5′-Pu-GA(T/A)TC-Py sequence. It serves as a potential payload for antibody–agent conjugates (ADCs) and is under research for cancer treatments [1] [2].

TC11 (1H-Isoindole-1,3(2H)-dione, 5-amino-2-[2,6-bis(1-methylethyl)phenyl]-TC11) is a potent inhibitor of tumor cell proliferation and an inducer of apoptosis via activation of caspase-3, 8 and 9.

AZD1446 HCl, also known as TC-6683, is a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. AZD1446 HCl showed favorable pharmaceutical properties and in vivo efficacy in animal models has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions and had been evaluated in phase 2 clinical trials as a treatment for Alzheimer's disease.

ML-336 is an inhibitor of of the Venezuelan equine encephalitis virus (VEEV) strain TC-83.

AZD1446 tosylate, also known as TC-6683, is a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. AZD1446 tosylate showed favorable pharmaceutical properties and in vivo efficacy in animal models has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions and had been evaluated in phase 2 clinical trials as a treatment for Alzheimer's disease.

TC-AC28 is a novel potent and selective Brd2(2) ligand.

Selective histone demethylase KDM2/7 subfamily inhibitor

PTP1B/AKR1B1-IN-1 is a dual inhibitor targeting protein tyrosine phosphatase 1B (PTP1B) and aldose reductase (AKR1B1), exhibiting inhibitory potency with IC50s of 0.06 μM for PTP1B and 4.3 μM for AKR1B1. Additionally, it inhibits T-cell protein tyrosine phosphatase (TC-PTP) with an IC50 of 9 μM. This compound acts as an insulin-mimetic in murine myoblasts and diminishes AKR1B1-mediated sorbitol accumulation, contributing to the management of blood glucose levels and the inhibition of type 2 diabetes mellitus (T2DM) development [1].

H-Tyr-Phe-OH (L-Tyrosyl-L-phenylalanine) can be used as the biomarker to distinguish benign thyroid nodules (BTN) from thyroid cancer (TC). H-Tyr-Phe-OH is an orally active Angiotensin-converting enzyme inhibitor with the 48% inhibiton rate at 50 μM. H-Tyr-Phe-OH shows xanthine oxidase inhibitory activity(uric acid lowering) that acts as regulator of IL-8 production in neutrophil-like cells [1] [2] [3] [4].

ROCK-IN-2 (Azaindole 1) is a selective and ATP-competitive ROCK inhibitor with IC50 of 0.6 and 1.1 nM for human ROCK-1 and ROCK-2.

Vandetanib Fumarate is an orally available tyrosine kinase inhibitor. Vandetanib Fumarate works by blocking RET (REarranged during Transfection), vascular endothelial growth factor receptor (VEGFR-2, VEGFR-3), and epidermal growth factor receptor and to a